Biotech Fund Doubles Down: Scholar Rock Bet Drives 26% Rally
A major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...
Learn how to choose a low-fee Dividend Aristocrats ETF and what fees to watch. This intro covers cost factors and quick tips for a cost-efficient selection.
24,603 articlesA major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...
A leading Substack economist warns that ghost gdp could erase friction in the economy, accelerating a white-collar re...
Two major travel stocks have caught the eye of billionaire activist investors. This article breaks down what could ha...
A sharp move in Thomson Reuters stock has investors buzzing. AI-powered products and enterprise deals are at the hear...
Hedge funds are chasing a single megacap, creating crowded trades. Learn what crowdedness means, how to read the sign...
Greycroft increased its Sportradar stake in a year where the stock fell sharply, illustrating how big investors respo...
Salesforce unveils a $50 billion buyback as software stocks waver, triggering a fierce debate over whether capital sh...
A young plaintiff testifies in a civil trial accusing major platforms of harming mental health, focusing on a compuls...
Compass is expanding its Texas footprint by acquiring Rogers Healy and Associates, a RealTrends Verified brokerage. T...
The Fed just rolled out a new emergency measure that could reshape how we borrow money. This article breaks down what...
Tensions around the Strait of Hormuz threaten a key energy route that could ripple through markets and household budg...
A veteran's take on holding (onon) 2025 earnings: what to watch, where margins could move, and how to plan for the Q4...